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An elevated ferritin level before allogeneic hematopoietic cell transplantation (HCT) is an adverse prognostic
factor for overall survival (OS) and nonrelapse mortality. Because ferritin is an imperfect surrogate of iron
stores, the prognostic role of iron overload remains unclear. We conducted a patient-level meta-analysis of
4 studies that used magnetic resonance imaging to estimate pre-HCT liver iron content (LIC). An elevated LIC
was not associated with a signiﬁcant increase in mortality: the hazard ratio (HR) for mortality associated with
LIC > 7 mg/g dry weight (primary endpoint) was 1.4 (P ¼ .18). In contrast, ferritin >1000 ng/mL was a sig-
niﬁcant prognostic factor (HR for mortality, 1.7; P ¼ .036). There was, however, no signiﬁcant association
between ferritin > 2500 and mortality. This meta-analysis suggests that iron overload, as assessed by LIC, is
not a strong prognostic factor for OS in a general adult HCT population. Our data also suggest that ferritin is an
inadequate surrogate for iron overload in HCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The toxicities of iron overload in patients with benign
diseases overlap with some of the most severe toxicities of
allogeneic hematopoietic cell transplantation (HCT), which
has led to the hypothesis that iron overload could be com-
mon and deleterious in patients with hematologic malig-
nancies undergoing HCT. A large body of evidence has shown
that an elevated serum ferritin (SF) before HCT is associated
with inferior overall survival (OS), an effect that, in most
studies, appears mediated by an increase in nonrelapse
mortality (NRM) [1-15]. Although those studies vary in their
study population and choice of SF cutoff, they almost uni-
versally agree that a high SF is associated with an adverse
prognosis. A more direct estimate of total body iron burden
may be obtained bymeasuring liver iron content (LIC), which
may be assessed noninvasively by magnetic resonance im-
aging (MRI) [16,17]. In HCT studies evaluating both LIC esti-
mated byMRI and SF, the correlation coefﬁcient between the
two is around .6 to .8 [12,13,18-21], implying that ferritin is
an acceptable but imperfect surrogate of true iron burden.edgments on page 1250.
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14.05.004Alternatively, because ferritin is an acute phase reactant,
its elevation in serum may betray inﬂammatory states,
including active infection or more advanced disease status,
which are expected to confer an adverse prognosis in HCT
independent of iron overload. There are at present 4 pub-
lished studies that have directly assessed the impact of
pre-HCT LIC on outcome, but they differ in their conclusion
despite their generally similar design [4,14,15,22]. We,
therefore, undertook an individual patient data meta-
analysis of all 4 studies, with the aim of clarifying whether
pre-HCT LIC is, like SF, associated with worse OS or NRM.
METHODS
We obtained patient-level data from the 4 published prospective studies
[3,12,13,22]. Survivors with < 6 months of post-HCT follow-up were
excluded. We conducted a meta-analysis for OS and NRM. NRM was calcu-
lated in the competing risks framework, treating relapse as a competing risk.
Within each study as awhole or for a subgroup of interest, we calculated the
hazard ratio (HR) and associated P value for mortality using a univariable
proportional hazardsmodel and for NRM using a competing risks regression
model [23]. The HRs were pooled with inverse variance weighting, using a
random effects model [24]. Heterogeneity was assessed using the Cochran’s
Q statistic and the I2 calculation [24,25].
RESULTS AND DISCUSSION
The details of the 4 cohorts and the 276 patients included
in this analysis have been previously published [4,14,15,22].
The median age was 52 (range, 18 to 74) years. One half had
acute myeloid leukemia and 16% had myelodysplastic syn-
drome. Almost two-thirds received reduced-intensity con-
ditioning (RIC). The median pre-HCT SF was 1523 (range, 20
Table 1
Summary Results
Population Outcome Variable HR (95 CI, P Value)
Overall cohort Overall survival LIC > 5 mg/gdw 1.0 (.6-1.5), P ¼ 1.00
LIC > 7 mg/gdw 1.4 (.9-2.3), P ¼ .20
SF > 1000 ng/mL 1.7 (1.0-2.7), P ¼ .036
SF > 2500 ng/mL 1.3 (.8-2.0), P ¼ .30
Nonrelapse mortality LIC > 5 mg/gdw 1.0 (.6-1.7), P ¼ .90
LIC > 7 mg/gdw 1.7 (.9-3.3), P ¼ .09
SF > 1000 ng/mL 1.6 (.9-2.8), P ¼ .14
SF > 2500 ng/mL 1.4 (.8-2.3), P ¼ .30
MAC cohort Overall survival LIC > 7 mg/gdw 1.3 (.4-4.4), P ¼ .60
SF > 1000 ng/mL 1.5 (.6-3.5), P ¼ .40
Nonrelapse mortality LIC > 7 mg/gdw Not evaluable*
SF > 1000 ng/mL
RIC cohorty Overall survival LIC > 7 mg/gdw 1.5 (.8-2.7), P ¼ .20
SF > 1000 ng/mL 1.5 (.8-2.8), P ¼ .20
Nonrelapse mortality LIC > 7 mg/gdw 2.2 (1.1-4.6), P ¼ .026y
SF > 1000 ng/mL 1.5 (.7-3.3), P ¼ .30
Acute leukemia þ MDS Overall survival LIC > 7 mg/gdw 1.2 (.7-2.3), P ¼ .60
SF > 1000 ng/mL 1.5 (.7-3.1), P ¼ .30
Nonrelapse mortality LIC > 7 mg/gdw 1.5 (.7-3.0), P ¼ .30
SF > 1000 ng/mL 1.1 (.6-2.2), P ¼ .70
HR denotes hazard ratio; 95 CI, 95% conﬁdence interval; LIC, liver iron content; gdw, gram dry weight; SF, serum ferritin; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning; MDS, myelodysplastic syndromes.
For each variable, outcome and subgroup of interest, the hazard ratio is given along with its associated 95% conﬁdence interval and P value.
* Not evaluable because of the small number of events in this subgroup.
y See text for comment.
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mL, and 23% above 2500 ng/mL. Themedian pre-HCT LIC was
5.0 (range, .3 to 25.4) mg/g dry weight (gdw), with 82% of
patients having an elevated LIC (>1.8 mg/gdw), 50% had an
LIC> 5mg/gdw, and 28% had an LIC> 7mg/gdw. Themedian
follow-up for survivors was 22 (range, 6 to 44) months.
The results are summarized in Table 1. We used 2 possible
prespeciﬁed thresholds for SF (1000 and 2500 ng/mL) and for
LIC (5 and 7mg/gdw), corresponding to thosemost often used
in the HCT literature and in the primary studies. For OS, the
pooled HR associated with LIC> 5 mg/gdwwas 1.0 (P ¼ 1.00)
(Figure 1A); for LIC > 7 mg/gdw, the HR was 1.4 (P ¼ .20)
(Figure1B). For ferritin>1000ng/mL, theHRwas1.7 (P¼ .036)
(Figure 1C); however, there was no signiﬁcant association
between ferritin> 2500 ng/mL andmortality (HR,1.3; P¼ .30)
(Figure 1D). There was no signiﬁcant heterogeneity for any of
the above outcomes (Q statistic, .1 to 2.7 with 3 degrees of
freedom; P values, .5 to 1.0; I2 ¼ 0 for all). There was no sig-
niﬁcant association between any of the variables studied and
NRM.We also found no signiﬁcant association between LIC or
SFandOSor TRM in analyses restricted to patients undergoing
myeloablative conditioning, or in the subgroup of patients
with myelodysplastic syndrome or acute leukemia. We also
conducted an exploratory analysis restricted to patients who
had undergone RIC HCT. The HR for NRM associated with LIC
> 7 mg/gdw was 2.2 (P ¼ .026), although the other HRs were
not signiﬁcant. One of the studies in this meta-analysis only
enrolledpatients undergoingmyeloablative conditioningHCT,
and this study was, therefore, not included in this subgroup
analysis. As the number of patients and of events in the anal-
ysis of NRM for RIC patients was small, those results should be
interpreted with caution. However, they raise the possibility
that iron overload may have a particular importance among
the generally older and frailer patients undergoing RIC HCT,
which deserves further study.
In summary, we did not ﬁnd a signiﬁcant association
between an elevated pre-HCT LIC and OS or NRM overall.Consistent with previous studies, we observed a signiﬁcant
association between SF and OS. However, this was only sig-
niﬁcant at a threshold of 1000 ng/mL and not at a threshold
of 2500 ng/mL. This could be explained if the adverse prog-
nosis of SF is related not to iron overload but to underlying
disease-related or comorbidity-related issues that elevate
acute phase reactants. In that case, the degree of elevation in
SF may not be relevant, only the presence of the underlying
issues reﬂected by any signiﬁcant elevation in SF. If this were
true, an SF threshold of 1000 ng/mL may better capture the
patient population at risk than a higher threshold. Regard-
less, our results suggest that the evidence to date on SF and
HCT outcome may not allow us to conclude that iron over-
load itself is strongly detrimental after HCT.
It is unlikely that our negative results stem from our
threshold choice. Based on prior reports of the correlation
between SF and LIC in this patient population [18], an SF of
2500 ng/mL corresponds to an LIC around 6 mg/gdw. There-
fore, the thresholds chosen for thismeta-analysis should have
captured the prognostic effect previously seen with SF. It is
also unlikely that our results are confounded bymeasurement
technique. Although the MRI techniques used to estimate LIC
differed among the 4 studies, they all used techniques that
have been previously validated against liver biopsy.
It is possible that given the trends for increased overall
and NRM for elevated LIC, our negative results reﬂect a
sample size issue, and that a larger study would have un-
covered a signiﬁcant effect. Our study also lacked power to
deﬁnitively study the impact of iron overload among patient
subgroups. Regardless, the results presented here should not
be interpreted to imply that iron is irrelevant in HCT. The
trends suggest a possible prognostic effect, although it does
not appear as strong as suspected based on the ferritin-
related literature, and it may be restricted to certain sub-
groups. Moreover, iron may be related to disease pathology
inways that are just beginning to be understood.We suggest,
instead, that the present study should serve as the impetus
Figure 1. Forest plot of the hazard ratios for mortality associated with LIC > 5 mg/gdw (A), LIC > 7 mg/gdw (B), ferritin >1000 ng/mL (C), and ferritin > 2500 ng/mL
(D). Center names are abbreviated as follows: DFCI indicates Dana-Farber Cancer Institute; Dresden, University of Dresden; Turku, Turku University Hospital; UMN,
University of Minnesota.
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primarily on SF measurement, and that explore, through
careful and creative design, alternative mechanisms through
which iron may inﬂuence HCT outcomes. Furthermore,
several groups have already reported on the use of [26-30] or
recommendation for [31] chelation therapy in the pre or
post-HCT setting. Our results may weaken the premise for
chelation studies in general transplantation populations, and
they may emphasize the need to design future chelation
studies with a broad array of correlative endpoints that could
uncover possible effects of chelation beyond simply the
reduction in iron stores.ACKNOWLEDGMENTS
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